If the coronavirus infection continues to increase in the country, Omicron may increase further towards the end of this month (January).
On Tuesday (January 18) Bangabandhu Sheikh Mujib Medical University (BSMMU) Genome Sequencing Research Project Chief Patron (Supervisor) Vice-Chancellor Prof. Dr. Md. Sharfuddin Ahmed gave this information.
He said that from December 6, 2021 to January 7, 2022, 20 per cent Omicron and 60 per cent Delta infected patients were found in the country by sequencing the genome of Kovid infected people. At the same time, all the victims of Delta variant were admitted to the hospital. Omicron was not detected in any of these admitted patients.
The vice-chancellor said that as the infection continues to grow, Omicron may increase further by the end of this month.
Sharfuddin Ahmed said that the purpose of genome sequencing research of Kevid-19 was to uncover the genome character of Kevid-11, the type of mutation and its interaction with the genome of global Kovid-19 virus and to create Bangladeshi Kovid-19 genome database. This report is the result of 6 (six) months 15 (fifteen) days of ongoing research of BSMMU, we hope to be able to report updated results in the coming weeks.
It is known that from 29 June 2021 to 6 January 2022, this study was conducted on patients all over the country infected with Kovid-19. Representative sampling of all departments of the country was done in the study. In the study, genome sequencing of coronavirus was performed through next-generation sequencing from a fairly pharyngeal swab sample of 69 Covid-19 positive patients.
The BSMMU study included patients ranging in age from 9 months to 90 years. The number of patients aged 21 to 56 is higher. Since Covid 19 is not immune to any age limit, so does Covid infection in children.
It was also found that among the patients suffering from covid, those who had co-morbidity, such as cancer, respiratory diseases, heart disease, diabetes, had the highest number of deaths. In addition, patients over the age of 60 have a higher risk of dying from a second infection.